The cellular pathogenesis of human benign prostatic hyperplasia is poorly understood. To understand the functional contribution of specific cell types in disease, a cellular atlas of the normal organ was created using single cell RNA sequencing (scRNA-seq) and immunofluorescence. These data were then used as a control to characterize cellular alterations in BPH.
INTRODUCTION AND OBJECTIVES:
The cellular pathogenesis of human benign prostatic hyperplasia is poorly understood. To understand the functional contribution of specific cell types in disease, a cellular atlas of the normal organ was created using single cell RNA sequencing (scRNA-seq) and immunofluorescence. These data were then used as a control to characterize cellular alterations in BPH.
METHODS: BPH tissue from three simple prostatectomy patients and normal prostate specimens from three young organ donors were digested into single cell suspensions. scRNA-seq was performed to derive a molecular profile of each cell type. Unsupervised clustering objectively identified known and novel cell types and newly derived molecular markers were used to 1) improve the flow cytometry-based isolation of individual cell types for functional analysis and 2) provide immunohistochemical confirmation of anatomical position in whole mount specimens. Bioinformatics analysis was used to derive differentially expressed genes for each cell type in normal prostate vs. BPH. Immunohistochemical analysis was used to confirm changes in cellular composition.
RESULTS: We identified two stromal cell types (DCNþ fibroblasts and MYH11þ smooth muscle) and five epithelial cell types (KRT14þ basal, KLK3þ luminal, and CHGAþ neuroendocrine, KRT13þ hillock, and SCGB1A1þ club) in silico. Whole mount immunohistochemical analysis of KRT13þ and SCGB1A1þ epithelial cell types revealed their enrichment in the prostatic urethra and proximal prostatic ducts and their expansion in glandular BPH. Fibroblasts were enriched in the anterior fibromuscular stroma and peri-urethral regions of the normal prostate and were expanded around the urethra in BPH with stromal hyperplasia. M2 macrophages, mast cells, and T cells were enriched in BPH.
CONCLUSIONS: An unbiased transcriptional identity of each cell type in the normal prostate is required for understanding functional interactions between cell types in homeostasis and disease. Our study provides the resources to identify, localize, and isolate every cell type in the human prostate. Our identification of novel epithelial cell types concentrated in the urethra and spread throughout the prostate could lead to a deeper understanding of the zonal anatomy and cellular origin of human prostate diseases. Our cell type-specific transcriptional profiles could be used to design new therapeutic agents in BPH. 
MP06-15 DIVERGENT EFFECTS OF THE P21-ACTIVATED KINASE (PAK) INHIBITORS FRAX486 AND IPA3 REFLECT DIFFERENT, ISOFORM-SPECIFIC PAK REGULATION OF THROMBOXANE A2-AND ENDOTHELIN-1-INDUCED PROSTATE SMOOTH MUSLCE CONTRACTIONS
Qingfeng Yu*, Bingsheng Li, Christian Gratzke, Alexander Tamalunas, Yiming Wang, Frank Strittmatter, Christian G. Stief, Martin Hennenberg, Munich, Germany INTRODUCTION AND OBJECTIVES: Alpha1-blockers are the major option for treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia, as they reduce urethral obstruction and symptoms by inhibition of a1-adrenergic prostate smooth muscle contraction. However, their efficacy is limited, as non-adrenergic mediators (thromboxane A2 (TXA2), endothelin-1) contribute to prostate smooth muscle tone in parallel to a1-adrenoceptors, what may keep prostate smooth muscle tone and symptoms despite application of a1-blockers. Novel compounds addressing nonadrenergic contractions in the prostate are required to develop future therapies with enhanced efficacy. Recently, inhibition of neurogenic and endothelin-induced prostate smooth muscle contraction by the p21-activated kinase (PAK) inhibitor FRAX486 has been reported. However, effects of PAK inhibitors on TXA2-induced contractions, and of other PAK inhibitors on endothelin-induced contractions are unknown. Here, we assessed effects of FRAX486 and IPA3 on nonadrenergic contractions of human prostate smooth muscle.
METHODS: Human prostate tissues were obtained from radical prostatectomy. Contractions of prostate strips were studied in an organ bath, where they were induced by endothelin-1 or the TXA2 analog U46619. Contractions were compared between whole corresponding groups (inhibitor vs. control) by two-way ANOVA, and at each single concentration by multivariate analysis.
RESULTS: U46619 (0.1-30 µM) and endothelin-1 (0.1-3 µM) induced concentration-dependent contractions of human prostate tissues. FRAX486 (30 µM) inhibited U46619-induced contractions, which was significant between whole groups (p<0.002 between FRAX486 and controls). Similarly, IPA3 (300 µM) inhibited U46619-induced contractions, which was significant between whole groups (p<0.005 between IPA3 and controls), and at 30 µM (p<0.05 between IPA3 and control). In contrast, IPA3 did not inhibit endothelin-1-induced contractions.
CONCLUSIONS: The divergent effects of both PAK inhibitors may reflect their different pharmacologic profiles, as FRAX486 is known to inhibit group I (PAK1-3) and group II PAKs (PAK4-6), while IPA3 inhibits only group II PAKs. Endothelin-and TXA2-induced contractions in the prostate are promoted by different PAK isoforms, so that FRAX486 as a pan-PAK inhibitor may be most promosing from a translational view.
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MP06-16 THE FUNCTIONAL ROLE OF ADENOSINE A2B RECEPTOR SUBTYPES IN THE BLADDER OF MALE RATS WITH BLADDER OUTLET OBSTRUCTION
Masahiro Kurobe*, Pittsburgh, PA; Ei-ichiro Takaoka, Narita, Japan; Takahisa Suzuki, Hamamatsu, Japan; Shinsuke Mizoguchi, Tetsuichi Saito, Pittsburgh, PA; Jun Miyazaki, Narita, Japan; Hiroyuki Nishiyama, Tsukuba, Japan; Edwin K. Jackson, Lori A. Birder, Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Previous studies on bladder outlet obstruction (BOO)-induced bladder dysfunction often utilized female rats. Also, recent studies using female rats have reported that adenosine receptor (AR) modulation can affect bladder function. However, the AR mechanism underlying BOO-related bladder dysfunction is not well elucidated, especially in male rats. Thus we examined the expression of AR subtypes after BOO, and the effects of adenosine A2B receptor (A2B-R) deletion on bladder activity using male rats.
METHODS: BOO was induced in male Sprague-Dawley rats by partial ligation of the proximal urethra. At 4 weeks after BOO, conscious cystometrograms (CMG) were performed with the urethral ligature intact. Sham operated animals were used as controls. mRNA levels of AR subtypes such as A1, A2A, A2B and A3 in bladder mucosa and detrusor layers were analyzed by RT-PCR. Furthermore, we examined the difference of bladder function between A2B-R knockout (A2BKO) and wild-type (WT) groups of male Dahl salt-sensitive rats by CMG.
RESULTS: Bladder weight of BOO rats was significantly increased compared to sham rats. In CMG, BOO rats exhibited Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e53
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